Phio Pharmaceuticals
Open
$1.23
Prev. Close
$1.23
High
$1.23
Low
$1.23
Market Snapshot
$12.7M
-1.5
-10.24
6
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company is headquartered in King Of Prussia, Pennsylvania and currently employs 6 full-time employees. The company went IPO on 2012-05-10. The firm's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The company is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The firm's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
emptyResult
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company is headquartered in King Of Prussia, Pennsylvania and currently employs 6 full-time employees. The company went IPO on 2012-05-10. The firm's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The company is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The firm's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
Recently from Cashu
Phio Pharmaceuticals: Key Developments and Future Outlook in the Biotech Sector
Certainly! Please provide the content you would like me to summarize, and I'll create an article based on it.
It seems there was an oversight, as no content was provided for summarization. Please share the content you'd like me to summarize, and I'll be happy to assist!
Please provide the content you would like me to summarize.
Please provide the text you would like me to summarize.
Sure! Please provide the text you would like me to summarize.
Phio Pharmaceuticals: Advancing Immunotherapy Trials with Promising Investor Sentiment
Phio Pharmaceuticals Advances in Clinical Research: A Beacon of Hope in Immunotherapy Phio Pharmaceuticals Corp. is making significant strides in its ongoing clinical trial, drawing attention for its…